I-Technivie (i-ombitasvir + paritaprevir + ritonavir) isalathisi esilungeleleneyo isilwanyana esisetyenziswe kunyango lwe- HTV (HCV) engapheliyo. Amathente amathathu aquka i-Technivie nayo ihlanganiswa kwiipilisi ezimbini ze-HCV, i- Viekira Pak .
I-Technivie yavunywa ngoJulayi 24, 2015 ngu-US Food and Drug Administration (FDA) ukusetyenziswa kubantu abadala kweminyaka eyi-18 okanye ngaphezulu nge-HCV ye-genotype 4 (GT4) ngaphandle kwe- cirrhosis .
I-Technivie ngowona wokuqala, uwonke-ngomlomo, unyango lwe-HCV olungenasiphelo kwi-HCV kwizigulane ze-GT4 ezingapheliyo zokusuleleka kwe-HCV, abantu ngokuqhelekileyo babonwa nzima ukunyanga.
I-Technivie yabikwa ukuba inezinga lokunyanga le-100% langaphambili elingakhange lithathwe ("i-naïve yonyango") izigulane kwisilingo seSigaba IIb esenziwa ngo-Agasti 12, 2012 ukuya kuNovemba 19, 2013.
Isistim
Iipilisi ezimbini (12.5mg ombitasvir, i-75mg paritaprevir, i-50mg ritonavir) ithathwa imihla ngemihla ngesidlo ngaphandle kwesidingo sokudla okunamafutha amaninzi okanye i-caloric. Amacwecwe e-Technivie anesipinki, i-oblong kunye nefilimu eboshwe, kunye ne "AV1" emacaleni kwelinye icala.
Ukucetyiswa kweengcebiso
I-Technivie imiselwe kwiikhosi eziyi-12 kunye ne-ribavirin (isilwanyana esisetyenziselwa ukuvimbela ukuveliswa kwe-RNA). I-dose ephakanyisiweyo ye-ribavirin isekelwe kwisisindo, ngolu hlobo:
- Ngaphantsi kwama-165 lbs (75kg): 1000mg yemihla ngemihla, ihlulwe kwaye ilawulwa kabini imihla ngemihla ngokutya
- 165 lbs (75kg) nangaphezulu: i-1250mg yemihla ngemihla, yahlula kwaye ilawulwa kabini imihla ngemihla ngokutya
Ikhosi ye-Technivie yeeveki ezili-12 iyakucatshangelwa yonyango i-naïve isigulane engakwazi ukunyamezela i-ribavirin.
Iziphumo eziPhakathi
Iziphumo eziqhelekileyo ezimalunga nokusetyenziswa kwe-Technivie (ezenzeka ubuncinane kwi-7% yezigulane) zi:
- Ukubuthathaka
- Ukukhathala
- I sizathu
- Ukungabikho
- Rash
IMilly Contraindicated
La machiza alandelayo akufanele athathwe xa usebenzisa i-Technivie:
- Anticonvulsants: Tegretol, Dilantin, Trileptal, phenobarbital
- Antipsychotics: Orap
- Iyeza-antiretroviral: Sustiva
- Izidakamizwa zokunciphisa i-cholesterol: i-Altoprev, iMevacor, iZocor
- Iyeza e-erectile yokungasebenzi: iReatio
- Izixhobo ezivela e-Ergot (ezisetyenziselwa unyango lweentloko): DHE 45, Ergomar, Ergotrate, Hydergine, Migranal
- I-Estinyl isradiol-containing containing contraceptives: i-Estinyl, i-Apri, i-Reclipsen, i-Azurette, i-Kariva, i-Yaz, i-Yasmin, i-Ocella, i-Vestura, i-Beyaz, i-Safyral, i-Zovia, i- Demulen, i-Demulen 1/35, i-Kelnor 1/35, i-Nuva Ring, i-FaLessa, i-Lutera, i-Alesse , Seasonique, Aviane, Ortho Evra, Xulane, Lo Loestrin Fe, Necon 1/35, Minastrin 24 Fe, Loestrin 24 Fe, Ortho Tri-Cyclen, Sprintec, Ortho Tri-Cyclen Lo, Tri-Sprintec, Cryselle, Lo / Ovral, Ovral, Elinest
- I-Rifampin-based based anti-tuberculosis amayeza: Mycobutin, Rifater, Rifamate, Rimactane, Rifadin, Priftin
- Iziqhelo: I-Versed, iHalcion
- ISt John's Wort
Ukungqinelana nokuqwalasela
I-Technivie ayikhuthazwa izigulane ezineempembelelo eziphambili ze-hepatic (i-Child-Pugh score B) kwaye iyaphikiswa kwizigulane ezinobungozi obunzima (i-Child-Pugh score C).
I-Technivie inqatshelwe ukusetyenziswa kwezigulane ezine-hypersensitivity eyaziwayo kwi- ritonavir (oko kukuthi, ngubani oye wabona uStevens-Johnson Syndrome okanye i-epidermal necrolysis enetyhefu).
Nangona i-Technivie iyodwa ingavunyelwanga ukuba isebenzise ekukhulelweni, ukuhlanganiswa kwe-Technivie kunye ne-ribavirin kwaye akufanele isetyenziswe kubafazi abakhulelweyo okanye amadoda anamaqabane abo abafazi abakhulelweyo. Ngokuphathelele ukuncelisa, akukho ziphumo zentengiso engavumelekanga yokuphuhlisa umntwana kwisifundo sezilwanyana; Ukucebisana kweengcali kucetyiswa ukuba kuxubushe iingeniso ezintle kunye nemiphumo emibi yokuncelisa xa i-Technivie.
Umthombo:
US Administration and Drug Administration (FDA). "I-FDA iyayivumela i-Technivie ukuba yonyango lwe-hepatitis C engapheliyo 4." Silver Spring, eMaryn; ukukhutshwa kwenkcazelo ekhutshwe ngoJulayi 24, 2015.
Hézode, C; Asselah, T .; Reddy, R .; okqhubekayo. "I-Ombitasvir kunye neparitaprevir kunye ne-ritonavir kunye okanye ngaphandle kwe-ribavirin kwizigulane ezinezigulane zonyango kunye ne-genotype 4 yokusuleleka kwintsholongwane ye-hepatitis C engapheliyo (PEARL-I). Lancet. NgoJuni 20, 2015; 384 (9986): 2502-2509.